Vertex Pharma’s $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio

Vertex Pharmaceuticals Inc.’s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company’s rare-disease franchise, analysts said Thursday.

Previous post Constellation Brands’ earnings beat buoyed by beer as wine and spirits stay weak
Next post CarMax’s stock drops after it misses analyst estimates for net income and revenue